Search Medical Condition
Please enter condition
Please choose location from dropdown

Friedrichsthal, Germany Clinical Trials

A listing of Friedrichsthal, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (49) clinical trials

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto Respimat (AERIAL )

The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto Respimat according to label after approximately 6 weeks in routine clinical practice. In visit 1, patient data on demographics, smoking status, medical history, breathlessness, general ...

Phase N/A

0.0 miles

Learn More »

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of Humira for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice. The primary objectives of the PMOS are to explore changes in health related care utilization data by the evaluation of: the number of missed ...

Phase N/A

2.25 miles

Learn More »

Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.

Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several attempts using chemotherapeutic agents have been undertaken to prevent this proliferation-process, but none of these was introduced into routine clinical practice. Until recently, it has been ...

Phase

2.25 miles

Learn More »

Argus II Retinal Prosthesis System Post-Market Surveillance Study

This study is being conducted to monitor the use of Argus II in a larger population than available within pre-market approval studies. Safety data will be monitored to ensure continued acceptability of risks to study participants, and an attempt will be made to include all eligible and willing participants implanted ...

Phase N/A

2.25 miles

Learn More »

A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice

This is a retrospective, multi-center observational cohort study. This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed by a selected number of countries in Europe, depending on apremilast local availability. The design of this apremilast retrospective ...

Phase N/A

3.79 miles

Learn More »

Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Treatment of the metastatic renal cell carcinoma (mRCC) has experienced fundamental changes within a very short period of time. In the past few years, introduction of various new substances for the treatment of mRCC has therefore resulted in new scientific research questions. Temsirolimus and sunitinib are current standard therapies in ...

Phase N/A

3.9 miles

Learn More »

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropenias and infections with FCR, bendamustine and rituximab (BR) must be considered in patients ...

Phase

3.9 miles

Learn More »

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer

Control Arm: Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = 50.4 Gy followed by a tumor bed boost sequentially 5 to 8 2.0 Gy = 10.0 Gy to 16.0 Gy, total dose 60.4 Gy to 66.4 Gy. or Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = ...

Phase

3.9 miles

Learn More »

Patient Preference for Pegfilgrastim (Neulasta ) Application Forms

Neutropenia is one of the most common side effects of myelosuppressive chemotherapy. Febrile neutropenia and infectious complications are associated with chemotherapy dose delays and reductions and an increased risk of hospitalization. Prophylaxis with recombinant G-CSFs reduces the incidence, severity and duration of CIN and the risk of developing FN. Pegfilgrastim ...

Phase N/A

3.9 miles

Learn More »

Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

The primary objective of this study is to determine the preliminary efficacy and safety of the combination of tirabrutinib and idelalisib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL). The study has a 6 patient per arm safety run-in to evaluate safety prior to the enrollment ...

Phase

4.47 miles

Learn More »